+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The role of histone methyltransferase EZH2 in myelodysplastic syndromes



The role of histone methyltransferase EZH2 in myelodysplastic syndromes



Expert Review of Hematology 5(2): 177-185



Previous epigenetics research in myelodysplastic syndromes (MDS) mainly focused on the DNA methylation of tumor suppressor genes. Recent studies reported that around 6% of MDS patients have several EZH2 mutations including missense, frameshift and truncated mutations. Histone methyltransferase EZH2 plays a critical role in epigenetic regulation as a bridge between histone methylation/deacetylation and DNA methylation. EZH2 is frequently overexpressed and considered to be an oncogene in cancers; nevertheless, EZH2 is considered as a candidate tumor suppressor gene in MDS due to EZH2 mutations associated with poor survival. Many questions still need further discussion. Moreover, 3-deazaneplanocin can reduce EZH2 levels and H3K27 trimethylation, and synergistic effects are seen in combination with DNA demethylation agents or histone deacetylation inhibitors. All of the above give us more chances to improve epigenetic therapy in MDS. Therefore, the molecular mechanisms of EZH2 in tumorigenesis and the role of EZH2 in MDS are studied.

(PDF emailed within 0-6 h: $19.90)

Accession: 056478146

Download citation: RISBibTeXText

PMID: 22475286

DOI: 10.1586/ehm.12.5


Related references

DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Seminars in Hematology 45(1): 23-30, 2008

Epigenetic modification in gliomas: role of the histone methyltransferase EZH2. Expert Opinion on Therapeutic Targets 18(10): 1197-1206, 2015

Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. Pharmacology & Therapeutics 165: 26-31, 2017

Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage. Oncotarget 9(12): 10585-10605, 2018

Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network 4(1): 83-90, 2006

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. Journal of Gastroenterology and Hepatology 26(1): 19-27, 2011

Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. Genes & Cancer 2(5): 585-592, 2011

The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD). Journal of Biological Chemistry 292(2): 706-722, 2016

EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer. Omics 21(12): 751-753, 2017

The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer. Omics 20(2): 123-125, 2016

The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination. Neoplasia 15(11): 1251-1261, 2014

The role of methyltransferase inhibitors in the management of the myelodysplastic syndromes. Cancer Control 11(6 Suppl): 11-15, 2004

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proceedings of the National Academy of Sciences of the United States of America 109(8): 2989-2994, 2012

Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo. Oncotargets and Therapy 10: 3131-3144, 2017

Specialized distribution of the histone methyltransferase Ezh2 in the nuclear apical region of round spermatids and its interaction with the histone variant H1t2. Journal of Andrology 33(5): 1058-1066, 2013